Drug Profile


Alternative Names: ACV-1; AVC 6.8; Vc1.1

Latest Information Update: 17 Jun 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator University of Melbourne
  • Developer Calzada; Metabolic Pharmaceuticals
  • Class Analgesics; Conotoxins
  • Mechanism of Action Cholinergic receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Discontinued Neuropathic pain; Postherpetic neuralgia

Most Recent Events

  • 02 Oct 2006 Metabolic has initiated enrolment in a phase IIa trial for Neuropathic Sciatic Pain in Australia
  • 28 Sep 2006 Phase-II clinical trials in Neuropathic pain in Australia (SC)
  • 25 May 2004 Preclinical trials in Pain in Australia (SC)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top